Challenges in the discontinuation of chronic hepatitis B antiviral agents

Table 2 Off-therapy virological relapse, clinical relapse, and hepatitis B surface antigen loss in chronic hepatitis B patients

Ref.	Country	n (%)	HBeAg-negative, n (%)	Follow-up time (mo)	Virological relapse rate (%)	Clinical relapse rate (%)	HBsAg loss, n (%)
Fung et al[67], 2004	Canada	27	27	18	44.4	25.9	NR1
Enomoto et al[68], 2008	Japan	22	22	48	68.7	68.7	NR
Yeh et al[69], 2009	Taiwan	71	0	15	26.8	26.8	0
Fung et al[70], 2009	Hongkong	22	0	20	63.6	31.8	NR
Wang et al[71], 2010	China	125	125	24	30.4	NR	NR
Kuo et al[72], 2010	Taiwan	124	0	> 12	66.1	66.1	NR
Cai et al[73], 2010	China	11	0	22	42.8	0	NR
Liu et al[74], 2011	China	61	61	15	50.8	45.9	8/61
Jung et al[75], 2011	South Korea	19	9	12	31.6	21	0
Chan et al[76], 2011	Hongkong	53	53	47	69.8	NR	9/53
Liang et al[77], 2011	Hongkong	84	43		44	14.3	NR
Chaung et al[78], 2012	United States	39	0	14	89.7	38.5	0
Hadziyannis et al[15], 2012	Greece	33	33	69	45.4	45.4	13/33
Ha et al[79], 2012	China	145	145	16	65.5	64.1	NR
Song et al[80], 2012	South Korea	48	0	18	41.6	NR	NR
He et al[81], 2013	China	66	66	17	28.8	NR	2/66
Kim et al[82], 2013	Korea	45	45	26	73.3	53.3	NR
Jeng et al[83], 2013	Taiwan	95	95	> 12	57.9	45.3	0/95
Kwon et al[84], 2013	South Korea	16	NR	32	25	25	2/16
Ridruejo et al[85], 2014	Argentina	35	0	15	25.7	NR	18/35
Sohn et al[86], 2014	South Korea	95	54	22	83.1	NR	0/95
Patwardhan et al[87], 2014	United States	33	33	36	63.6	48.5	0/33
He et al[88], 2014	China	97	0	32	8.2	1	11/97
Chen et al[40], 2014	Taiwan	188	105	49	66.5	NR	33/185
Jiang et al[89], 2015	China	72	39	13	65.3	41.7	NR
Seto et al[90], 2015	Hongkong	184	184	12	91.8	22.8	0
Peng et al[91], 2015	China	65	21	12	43.1	27.7	1/65
Jeng et al[92], 2016	Taiwan	85	85	155	69	52	2/85
Qiu et al[93], 2016	China	112	0	52	48.2	NR	1/112
Yao et al[94], 2017	Taiwan	119	119	6 yr	25.2	12.7	44/1192
Cao et al[95], 2017	China	82	22	91	70.7	34.1	5/82
Chen et al[96], 2018	Taiwan	143	104	104	67.1	48.9	7/143
Hung et al[97], 2017	Taiwan	73	73	6 yr	54.8	6.8	20/73
Berg et al[42], 2017	German	21	21	144	52	23	4/21
Jeng et al[33], 2018	Taiwan	691	691	6 yr	79.2	60.6	42/691
Liem et al[39], 2019	Canada	45	27	72	71	13	1/45
Kaewdech et al[12], 2020	Thailand	92	70	48	63	33.7	2/92

¹Not reported.

²All patients had hepatitis B surface antigen level < 200 IU/mL at the end of treatment.

EOT: End of treatment; HBsAg: Hepatitis B surface antigen; NR: Not reported.